No abstract

Objective. To evaluate therapeutic efficacy and safety of Enterosgel adsorbent and compare it with standard therapy in children with viral hepatitis Patients and methods. This open-label, prospective, randomized, controlled trial was conducted in the Regional Hospital for Infectious Diseases of Karaganda. We examined 98 children (mean age 10.56 ± 0.36 years) diagnosed with hepatitis A. The diagnosis was verified by identification of the marker reflecting active replication of hepatitis A virus (аnti-HAV IgM) using enzyme-linked immunosorbent assay. We evaluated the dynamics of clinical symptoms and liver function tests, including total bilirubin and its fractions, as well as levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The experimental group included 52 patients who received Enterosgel; the control group comprised 46 patients who received standard for hepatitis A therapy. Results. Enterosgel ensured more rapid resolution of clinical symptoms of acute hepatitis A and normalization of liver function tests compared to patients with the control group. This led to a shorter period of intoxication, vomiting, and jaundice, as well as to reduced ALT, and shorter in-hospital stay. Key words: hepatitis A, intoxication, jaundice, enterosorbent, Enterosgel

No abstract